Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Cystic Fibrosis

Interventions

DRUG

Hyperpolarized Xenon

Inhaled contrast for MRI occurring at each of 4 visits.

Trial Locations (1)

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT02848560 - Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI | Biotech Hunter | Biotech Hunter